Inside Therapeutics

What Inside Therapeutics does

Inside Therapeutics is a French deeptech biotechnology company founded in July 2022 by five co-founders — Thomas Guerinier (CEO), Matthieu Kerhuel (CTO), Audrey Nsamela (CSO), Robin Oliveres (CBO), and Alexis Peyroles (Chairman, ex-CEO of OSE Immunotherapeutics) — to commercialize microfluidic-based systems for the formulation of lipid nanoparticles used in RNA therapeutics. The company designs and manufactures the TAMARA plug-and-play nanoparticle and RNA-LNP formulation system, which integrates Elveflow OB1 flow control with recyclable dual-geometry microfluidic chips (combining herringbone and baffle mixers) to span R&D volumes from 200 µL to 30 mL. Its NanoPULSE platform extends the underlying micromixing technology toward seamless scale-up from discovery to clinical manufacturing, supported by 5 patents anchored in CSO Audrey Nsamela's PhD research on nucleation physics of LNPs and liposomes. The product portfolio also includes LNP Starter Kits, Custom LNP Packs, and complementary CRO formulation services plus RNA-LNP training programs.

The business operates a hybrid revenue model combining capital equipment sales (TAMARA hardware with reusable consumable chips), recurring consumable revenue (lipid premix kits and replacement chips), and project-based professional services (CRO formulation projects from proof-of-concept to preclinical scale-up, plus training). Customer segmentation is vertical: academic and research institutions, biotech companies developing RNA therapeutics, and large pharmaceutical companies. The company serves 75+ active users globally and reports 30+ customers including Eli Lilly, Servier, OSE Immunotherapeutics, and several leading academic centers (Institut Pasteur, UMC Utrecht, ETH Zurich, UCL London, UPenn).

Go-to-market combines direct sales for the European and enterprise base with an exclusive distribution network spanning 11+ geographies — IDEX MPT (US/Canada), Analytik (UK/Ireland), Young Jin (Korea), Trend Bio (Australia/NZ), Altmann (Brazil), Integrated Bio (Taiwan), and KinRay (China). Strategic technology and supply partnerships include MGA MedTech for industrial production (announced October 2025), Elveflow for flow control integration, Corden Pharma for GMP-grade lipid supply, and the MINT Laboratory at University of Angers for academic collaboration. The company has raised approximately €4 million total across a €1.3M seed round (June 2024), an earlier round, and a €1M second round led by Aquiti Gestion (June 2025), with Newfund (Heka and NAEH funds) and Skalepark as continuing backers. Recognition includes the i-Lab award from the French government (2024) and the Bpifrance Deeptech label.

Name

Inside Therapeutics

Legal name

Inside Therapeutics

Website

https://insidetx.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Inside Therapeutics is a French deeptech company that designs and manufactures the TAMARA microfluidic system for RNA-LNP and nanoparticle formulation, serving academic, biotech, and pharmaceutical customers developing RNA therapeutics.

Ownership category

akta.pro rank

Product category

Microfluidic Nanoparticle and RNA-LNP Formulation Equipment

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

akta.pro secondary industry

RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF)

Keywords

• Microfluidic nanoparticle formulation
• RNA-LNP drug delivery
• Lipid nanoparticle manufacturing
• CRO formulation services
• Nanomedicine laboratory equipment

Headquarters

HQ city

Angoulême

HQ country

France

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

1. TAMARA Hardware Sales: Sale of TAMARA nanoparticle formulation systems including microfluidic controllers and reusable chips. One-time capital equipment purchase with recurring chip consumables.
2. Consumables: LNP Starter Kits (lipid premix for LNP formulation), Custom LNP Packs, and replacement microfluidic chips for TAMARA system.
3. CRO Formulation Services: End-to-end RNA-LNP formulation services from proof-of-concept to preclinical scale-up. Includes optimization studies, preclinical batches up to 100mL, and physicochemical characterization.
4. Training Services: RNA-LNP formulation training programs taking users from theory to practice to achieve autonomy in RNA-LNP workflows.

Pricing tiers

Go-to-market motion3 records

Distribution channels8 records

Marketing channels6 records

Core offering

Inside Therapeutics designs, manufactures, and sells the TAMARA microfluidic nanoparticle and RNA-LNP formulation system for research and preclinical use, along with LNP Starter Kits and Custom LNP Packs consumables, CRO formulation services, and RNA-LNP training programs. The TAMARA platform combines dual-mixer microfluidic chips, zero-waste fluidic design, and Elveflow OB1 flow control integration to enable reproducible formulation from 0.2 mL to 30 mL scales.

Product overview

Inside Therapeutics offers a portfolio of nanoparticle and RNA-LNP formulation products and services centered on its core TAMARA microfluidic platform. The TAMARA system serves as the flagship plug-and-play hardware product, complemented by LNP Starter Kits and Custom LNP Packs for consumables. Services include formulation CRO services (end-to-end LNP formulation) and RNA-LNP training programs. The portfolio is designed to cover the full development pipeline from early R&D screening (200 µL scale) through preclinical scale-up (up to 100 mL), enabling seamless transition from discovery to clinic.

Differentiator

Problem solved

Functional benefit

Brands

• TAMARA: Nanoparticle & LNP Formulation System - a plug-and-play microfluidic system for RNA-LNP and nanoparticle formulation covering all stages of R&D
• NanoPULSE
• LNP Starter Kits
• Custom LNP Pack

Products and services

• TAMARA Nanoparticle & LNP Formulation System A fully integrated, plug-and-play microfluidic system that simplifies and accelerates the development of LNPs and other nanoparticles. Supports volumes from 200 µL to 30 mL, featuring recyclable dual-design microfluidic chips (baffle and herringbone mixers), precise formulation parameter control (TFR, FRR), and zero-waste design for near 100% sample recovery. Targeted at academic researchers, biotech companies, and pharmaceutical companies working on RNA therapeutics and nanomedicine.
• LNP Starter Kits Lipid premix kits for LNP formulation, providing standardized starting materials for RNA-LNP development with the TAMARA system. Targeted at researchers and developers of RNA-LNP formulations across academic and industry settings.
• Custom LNP Pack Custom LNP research kit for tailored nanoparticle formulation needs, complementing the TAMARA platform for teams requiring bespoke lipid nanoparticle compositions. Targeted at researchers formulating novel RNA-LNP candidates.
• Formulation Service (CRO) End-to-end LNP formulation CRO service covering mRNA, siRNA, saRNA and more, from proof-of-concept to optimization and scale-up. Includes comprehensive physicochemical characterization and access to GMP-grade lipids. Targeted at biotech and pharma teams needing formulation expertise and preclinical batches up to 100 mL.
• RNA-LNP Training Hands-on training service enabling research and development teams to achieve autonomy in RNA-LNP formulation workflows, from theory to practice using expertise and best practices. Targeted at academic and industry teams adopting TAMARA or pursuing in-house RNA-LNP capabilities.

Quantifiable outcome

• Particle size adjustable 50-300nm with PDI below 0.2
• +4 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Partnerships

13 partnerships are on record, tiered strategic, minor and core.

• OSE ImmunotherapeuticsstrategicStrategic or Co-development Partner · 1 April 2026Biotech partnership within mRNA-LNP therapy era. Collaboration in HexARN project developing mRNA-LNP platform for innovative targeted therapies from development to production.
• InnoProductminorImplementation/ SI/ Consulting Partner · 19 March 2026Engineering consultancy supporting mechanical design, rapid prototyping, and industrial support for product development.
• MGA MedTechcoreStrategic or Co-development Partner · 1 October 2025Industrial partnership for production of TAMARA platform. MGA MedTech applies engineering expertise and Industry 4.0 facility to manufacture high-precision medical devices. €10 million Mably facility (4,000 m²) with advanced robotics and digitalization. Initial 5 TAMARA units delivered September 2025.
• Microfluidics from IDEX MPTcoreChannel Partner/ Reseller/ Distributor · 5 May 2025Exclusive distribution partnership for TAMARA nanoparticle formulation system in USA and Canada. IDEX MPT brings decades of nanoparticle processing experience and top-down formulation through Microfluidizer Technology. Together the technologies span full spectrum of nanoparticle development from discovery to full-scale production.
• MINT Laboratory (University of Angers/INSERM/CNRS)strategicStrategic or Co-development Partner · 1 January 2025Academic partnership including jointly supervised PhD thesis and HexARN program. MINT has 40 researchers with expertise in physical-chemistry, pharmaceutical technology, and biological evaluation. SynNanoVect platform for formulation and characterization.
• Corden PharmastrategicTechnology or IntegrationPartnership for GMP-grade lipid supply including ALC-0315 (BioNTech/Pfizer), SM-102 (Moderna), LP-01 (Novartis/Intellia), DOTAP, DODMA and more for scalable high-performance formulations.
• ElveflowstrategicTechnology or IntegrationStrategic technological partnership for OB1 microfluidic flow controller integration, providing precise contact-free flow control and eliminating cross-contamination risks.
• Analytik Ltd.minorChannel Partner/ Reseller/ DistributorUK and Ireland distributor specializing in cutting-edge scientific instruments for spectroscopy, particle characterisation, and more.
• Young Jin CorporationminorChannel Partner/ Reseller/ DistributorKorea specialist distributor of advanced biological, emulsion and nanoparticle formulation systems for pharma and biotech.
• Trend BiominorChannel Partner/ Reseller/ DistributorAustralia and New Zealand distributor of scientific instruments and consumables for life sciences.
• Altmann S.A.minorChannel Partner/ Reseller/ DistributorBrazilian distributor since 1935 for scientific and analytical instruments serving research, pharma, and quality control labs.
• Integrated Bio Ltd.minorChannel Partner/ Reseller/ DistributorTaiwan distributor serving academic research and biotechnology industries with life science tools and reagents.
• KinRayminorChannel Partner/ Reseller/ DistributorShanghai-based distributor supporting academic research institutes, biotech companies, and pharmaceutical laboratories in China.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Precision NanoSystems (Cytiva, Danaher): Pioneer of microfluidic LNP/nanoparticle formulation with the NanoAssemblr platform, now part of Cytiva/Danaher. Directly competes with Inside Therapeutics in RNA-LNP formulation equipment for pharma and biotech.
• Dolomite Microfluidics (Blacktrace): Designs and manufactures microfluidic systems and chips for nanoparticle and emulsion formulation, serving pharma, biotech, and academic customers. Overlaps with Inside Therapeutics in microfluidic LNP and drug delivery research tools.
• Syrris (Blacktrace): Specializes in microfluidic systems for nanoparticle formulation and process chemistry. Competes in the same microfluidic LNP/nano-emulsion R&D equipment category as Inside Therapeutics.

Others

• Microfluidics from IDEX MPT: Inside Therapeutics' exclusive North America distributor and a complementary microfluidic processing provider (Microfluidizer top-down formulation). Acts as both channel partner and adjacent competitor in nanoparticle manufacturing.

Emerging players

• Fluigent: Provides microfluidic flow control and pressure-based systems widely used in droplet, nanoparticle, and LNP research. Overlaps with Inside Therapeutics' microfluidic instrumentation customer base, particularly in academic labs.

Broad incumbents

• Cytiva (Danaher): Large life sciences tools and bioprocessing platform that acquired Precision NanoSystems. Offers broad product portfolio spanning discovery through manufacturing, making it a powerful incumbent Inside Therapeutics must compete against for pharma wallet share.
• Thermo Fisher Scientific: Global life sciences tools and instrumentation leader. Provides adjacent and overlapping products (particle characterization, bioprocessing) and could enter or expand in the LNP formulation equipment space.
• Agilent Technologies: Analytical instruments and life science tools provider with capabilities in particle characterization and biopharma workflows. Broad incumbent that competes for life sciences equipment budgets at pharma customers.
• Sartorius: Bioprocessing and lab products provider serving pharma and biotech manufacturing. Relevant incumbent for any expansion of Inside Therapeutics into clinical and commercial-scale bioprocessing.
• Bio-Techne: Life sciences research tools and consumables provider with exposure to RNA therapeutics and cell/gene therapy workflows. Competes for similar academic and biotech tooling budgets.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/insidetx

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inside Therapeutics